Literature DB >> 33958145

Molecular Biology of Bladder Cancer: Potential Implications for Therapy.

David J McConkey1.   

Abstract

Recently completed studies provided high-resolution descriptions of the molecular biological characteristics of urothelial bladder cancers. Whole transcriptome messenger RNA expression profiling revealed that they can be grouped into basal and luminal molecular subtypes resembling the ones described in breast cancers. Retrospective DNA sequencing efforts revealed roles for disruption of DNA damage response pathways in response to conventional chemotherapy and immune checkpoint blockade, and completed and ongoing studies indicate that the molecular biological properties of infiltrating host cells dictate also influence therapeutic outcomes. This article reviews these findings and identify gaps in knowledge that represent opportunities for future research.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cisplatin; FGFR3; Immune checkpoint blockade; Molecular subtypes; Neoadjuvant; Variant histology

Mesh:

Substances:

Year:  2021        PMID: 33958145     DOI: 10.1016/j.hoc.2021.02.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  1 in total

1.  The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer.

Authors:  Consuelo Amantini; Federica Maggi; Jacopo Adolfo Rossi de Vermandois; Marilena Gubbiotti; Antonella Giannantoni; Ettore Mearini; Massimo Nabissi; Daniele Tomassoni; Giorgio Santoni; Maria Beatrice Morelli
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.